TuHURA Biosciences (HURA) Price & Analysis

Compare

965 Followers

HURA Stock Chart & Stats

$2.52

-$0.03(-0.55%)

At close: Jan 08 4:00 PM EST

$2.52

-$0.03(-0.55%)

Day’s Range― - ―

52-Week Range$1.80 - $7.20

Previous CloseN/A

Volume116.05K

Average Volume (3M)215.15K

Market Cap

$127.76M

Enterprise Value$91.68M

Total Cash (Recent Filing)$8.51M

Total Debt (Recent Filing)$558.97K

Price to Earnings (P/E)―

Beta0.96

Next Earnings

Sep 30, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding51,103,535

10 Day Avg. Volume212,396

30 Day Avg. Volume215,145

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)5.23

Price to Sales (P/S)0.00

P/FCF Ratio-5.16

Enterprise Value/Market Cap0.72

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-5.20K

Enterprise Value/Ebitda-5.34

Forecast

1Y Price Target

$13.50

Price Target Upside435.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsUpcoming catalysts include enrollment updates and trial initiations, which could positively impact the company's future.

Market OutlookThe analyst reiterates a Buy rating and a 12-month price target of $12 per share.

Strategic AcquisitionThe acquisition with Kineta completed in June brings on board the anti-VISTA checkpoint inhibitor (CPI), now called TBS-2025, marking a significant milestone for TuHURA.

Bears Say

Financial PerformanceTuHURA Biosciences reported a net loss of $0.21 per share—wider than previously estimated.

Operational ExpensesR&D and SG&A expenses were higher than expected.

Potential RisksRisks include negative clinical results, delays, regulatory challenges, competitive risks, and long-term dilution risk.

TuHURA Biosciences News

TuHURA Biosciences files $250M mixed securities shelf

17:33 EST TuHURA Biosciences (HURA) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

7d ago

HURA

TuHURA Biosciences Announces $50M Stock Offering Agreement

An announcement from TuHURA Biosciences ( ($HURA) ) is now available. On November 3, 2025, TuHURA Biosciences entered...

6d ago

HURA

TuHURA Biosciences Plans Phase 2 Trial for TBS-2025

An update from TuHURA Biosciences ( ($HURA) ) is now available. In June 2025, TuHURA Biosciences initiated a...

7d ago

HURA

TuHURA Biosciences Secures $3M Bridge Loan Agreement

TuHURA Biosciences ( ($HURA) ) has shared an announcement. On October 27, 2025, TuHURA Biosciences entered into a...

10d ago

HURA

Tuhura Biosciences Advances in Merkel Cell Carcinoma Treatment Study

Tuhura Biosciences, Inc. (($HURA)) announced an update on their ongoing clinical study. Study Overview: Tuhura Biosciences, Inc. is...

14d ago

HURA

Tuhura Biosciences’ Promising Phase 1 Trial: A Potential Game-Changer in Merkel Cell Carcinoma Treatment

Tuhura Biosciences, Inc. (($HURA)) announced an update on their ongoing clinical study. Study Overview: Tuhura Biosciences, Inc. is...

14d ago

HURA

TuHURA Biosciences Extends Warrant Expiration to 2030

An update from TuHURA Biosciences ( ($HURA) ) is now available. On June 2, 2025, TuHURA Biosciences entered...

2M ago

HURA

Buy Rating on TuHURA Biosciences: Strategic Financial Projections and Upcoming Catalysts Drive Growth Potential

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on HURA stock, giving a Buy rating on...

3M ago

HURA

TuHURA Biosciences Advances Clinical Trials and Strengthens Market Position

TuHURA Biosciences ( ($HURA) ) has issued an announcement. TuHURA Biosciences has announced significant advancements in its clinical...

3M ago

HURA

TuHURA Biosciences files to sell 4.76M shares of common stock for holders

16:35 EDT TuHURA Biosciences (HURA) files to sell 4.76M shares of common stock for holders Published first on...

3M ago

HURA

TuHURA Biosciences included in Russell 3000 and 2000 Indexes

TuHURA Biosciences (HURA) has been added to the Russell 3000 Index, with automatic inclusion in the Russell 2000...

4M ago

HURA

TuHURA Biosciences Completes Acquisition of Kineta, Inc.

TuHURA Biosciences ( ($HURA) ) has shared an announcement. On June 30, 2025, TuHURA Biosciences completed its acquisition...

4M ago

HURA

TuHURA Biosciences Increases Authorized Common Stock Shares

An announcement from TuHURA Biosciences ( ($HURA) ) is now available. On June 23, 2025, TuHURA Biosciences‘ stockholders...

5M ago

HURA

TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma

TuHURA Biosciences (HURA) initiated its Phase 3 accelerated approval trial of IFx-2.0, TuHURA’s lead innate immune agonist, in...

5M ago

HURA

HURA FAQ

What was TuHURA Biosciences’s price range in the past 12 months?

TuHURA Biosciences lowest stock price was $1.80 and its highest was $7.20 in the past 12 months.

What is TuHURA Biosciences’s market cap?

TuHURA Biosciences’s market cap is $127.76M.

When is TuHURA Biosciences’s upcoming earnings report date?

TuHURA Biosciences’s upcoming earnings report date is Sep 30, 2025 which is 41 days ago.

How were TuHURA Biosciences’s earnings last quarter?

TuHURA Biosciences released its earnings results on Aug 14, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.07.

Is TuHURA Biosciences overvalued?

According to Wall Street analysts TuHURA Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TuHURA Biosciences pay dividends?

TuHURA Biosciences does not currently pay dividends.

What is TuHURA Biosciences’s EPS estimate?

TuHURA Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TuHURA Biosciences have?

TuHURA Biosciences has 51,103,535 shares outstanding.

What happened to TuHURA Biosciences’s price movement after its last earnings report?

TuHURA Biosciences reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 0.405%.

Which hedge fund is a major shareholder of TuHURA Biosciences?

Currently, no hedge funds are holding shares in HURA

TuHURA Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-287.92%

Trailing 12-Months

Asset Growth

1736.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

TuHURA Biosciences

TuHURA Biosciences (HURA) is a biotechnology company focused on the development and commercialization of innovative therapeutics and diagnostics in the field of personalized medicine. The company operates primarily in the pharmaceutical and healthcare sectors, leveraging cutting-edge genomic technologies to create targeted treatment solutions. Its core products include proprietary diagnostic tests and personalized therapeutic interventions aimed at improving patient outcomes across various disease areas.

TuHURA Biosciences (HURA) Earnings & Revenues

Historic Earnings Reports

HURA Stock 12 Month Forecast

Average Price Target

$13.50

▲(435.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","132":"$132","263":"$263","66.5":"$66.5","197.5":"$197.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,66.5,132,197.5,263],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,3.3692307692307693,4.338461538461538,5.3076923076923075,6.276923076923077,7.246153846153845,8.215384615384615,9.184615384615384,10.153846153846153,11.123076923076923,12.092307692307692,13.061538461538461,14.03076923076923,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,3.253846153846154,4.107692307692307,4.961538461538462,5.815384615384615,6.669230769230769,7.523076923076923,8.376923076923077,9.23076923076923,10.084615384615384,10.938461538461539,11.792307692307693,12.646153846153846,{"y":13.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.4,3.1384615384615384,3.8769230769230765,4.615384615384615,5.3538461538461535,6.092307692307692,6.83076923076923,7.569230769230769,8.307692307692307,9.046153846153846,9.784615384615384,10.523076923076923,11.26153846153846,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":262.15,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.65,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.6,"date":1675209600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":141.05,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.62,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.41,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >